Structure-Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796)

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4676-4686

  Regan, John ^a   Capolino, Alison ^a   Cirillo, Pier F ^a   Gilmore, Thomas ^a   Graham, Anne G ^a   Hickey, Eugene ^a   Kroe, Rachel R ^a   Madwed, Jeffrey ^a   Moriak, Monica ^a   Nelson, Richard ^a   Pargellis, Christopher A ^a   Swinamer, Alan ^a   Torcellini, Carol ^a   Tsang, Michele ^a   Moss, Neil ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 TERT BUTYL 2 (4 TOLYL 2H PYRAZOL 3 YL)] 3 [4 (2 MORPHOLIN 4 YLETHOXY)NAPHTHALEN 1 YL]UREA; ADENOSINE TRIPHOSPHATE; AROMATIC COMPOUND; DORAMAPIMOD; IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MORPHOLINE; PHOSPHOTRANSFERASE; PYRAZOLE DERIVATIVE; PYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENATURATION; DRUG POTENCY; HUMAN; HUMAN CELL; HYDROGEN BOND; LIPOPHILICITY; MELTING POINT; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEATING; HUMANS; LIGANDS; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 14; MITOGEN-ACTIVATED PROTEIN KINASES; NAPHTHALENES; PROTEIN BINDING; PROTEIN DENATURATION; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; UREA;

EID: 0142028917     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030121k     Document Type: Article

References (35)

1. Dinarello, C. A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 1991, 3, 941-948.
2. Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497.
3. Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
4. Maini, R.; St. Clair, E. W.; Breedveld, F.; Furst, D.; Kalden, J.; Weisman, M.; Smolen, J.; Emery, P.; Harriman, G.; Feldmann, M.; Lipsky, P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354, 1932-1939.
5. Present, D. H.; Rutgeerts, P.; Targan, S.; Hanauer, S. B.; Mayer, L.; van Hogezand, R. A.; Podolsky, D. K.; Sands, B. E.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; van Deventer, S. J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999, 340, 1398-1405.
6. Bresnihan, B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs 2001, 15, 87-97.
7. Jarvis, B.; Faulds, D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999, 57, 945-966.
8. Garrison, L.; McDonnell, N. D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58 Suppl 1, 65-169.
9. Mease, P. J.; Goffe, B. S.; Metz, J.; VanderStoep, A.; Finck, B.; Burge, D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356, 385-390.
10. Carteron, N. L. Cytokines in rheumatoid arthritis: trials and tribulations. Mol. Med. Today 2000, 6, 315-323.
11. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S. ; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P. ; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
12. Tibbles, L. A.; Woodgett, J. R. The stress-activated protein kinase pathways. Cell. Mol. Life Sci. 1999, 55, 1230-1254.
13. Ono, K.; Han, J. The p38 signal transduction pathway. Activation and function. Cell. Signalling 2000, 12, 1-13.
14. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82, 389-397.
15. Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823.
16. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 1996, 279, 1453-1461.
17. Gao, F.; Yue, T. L.; Shi, D. W.; Christopher, T. A.; Lopez, B. L.; Ohlstein, E. H.; Barone, F. C.; Ma, X. L. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc. Res. 2002, 53, 414-422.
18. Clark, W. M.; Lutsep, H. L. Potential of anticytokine therapies in central nervous system ischemia. Expert Opin. Biol. Ther. 2001, 1, 227-237.
19. Du, Y.; Ma, Z.; Lin, S.; Dodel, R. C.; Gao, F.; Bales, K. R.; Triarhou, L. C.; Chernet, E.; Perry, K. W.; Nelson, D. L.; Luecke, S.; Phebus, L. A.; Bymaster, F. P.; Paul, S. M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14669-14674.
20. Junn, E.; Mouradian, M. M. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J. Neurochem. 2001, 78, 374-383.
21. Newton, R.; Holden, N. Inhibitors of p38 Mitogen-Activated Protein Kinase: Potential as Anti-inflammatory Agents in Asthma? Biodrugs 2003, 17, 113-129.
22. Schultz, R. M. Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog. Drug Res. 2003, 60, 59-92.
23. Pargellis, C.; Regan, J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Invest. Drugs 2003, 4, 566-571.
24. Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem. 2001, 38, 1-60.
25. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2002, 2, 1009-1018.
26. Cirillo, P. F.; Pargellis, C. A.; Regan, J. The nondiaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2002, 2, 1021-1035.
27. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E. R.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C. A.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
28. Pargellis, C. A.; Tong, L.; Churchill, L.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 map kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
29. Branger, J.; van den Blink, B.; Weijer, S.; Madwed, J.; Bos, C. L.; Gupta, A.; Polmar, S. H.; Olszyna, D. P.; Hack, C. E.; van Deventer, S. J. H.; Peppelenbosch, M. P.; van der Poll, T. Antiinflammatory effects of a p38 mitogen activated protein kinase inhibitor, BIRB 796 BS, during human endotoxemia. J. Immunol. 2002, 168, 4070-4077.
30. Kroe, R. R.; Regan, J.; Proto, A.; Peet, G. W.; Roy, T.; Dickert, L.; Fuschetto, N.; Pargellis, C. A.; Ingraham, R. H. Thermal denaturation: A method to rank slow binding, high-affinity p38α MAP kinase inhibitors. J. Med. Chem. 2003, 46, 4669-4675.
31. Liu, M. C.; Lin, T. S.; Sartorelli, A. C. A one-pot synthesis of 3-nitro- and 3,5-dinitro-2-picolines. Synth. Comm. 1990, 20, 2965-2970.
32. Thavonekham, B. A practical synthesis of ureas from phenyl carbamates. Synthesis 1997, 1189-1194.
33. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in the synthesis and transformation of natural products. Synthesis 1981, 1-28.
34. Human p38-α and murine p38-α differ by two amino acids: Leu47 to His47 and Thr262 to Ala262. We have shown that these differences have negligible effects on the binding affinity for this class of inhibitors (data not shown).
35. Abraham, M. H.; Duce, P. P.; Prior, D. V.; Barratt, D. G.; Morris, J. J. ; Taylor, P. J. Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design. J. Chem. Soc., Perkin Trans. 2 1989, 1355-1375.